Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 48 of 182 for:    ERYTHROMYCIN

To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02528760
Recruitment Status : Completed
First Posted : August 19, 2015
Last Update Posted : November 21, 2017
Sponsor:
Information provided by (Responsible Party):
Institute of Liver and Biliary Sciences, India

Brief Summary:
  1. All patients with chronic liver disease admitted in ICU (Intensive Care Unit) to be screened.
  2. Patients fulfilling criteria for feed intolerance to be included in the study.
  3. Patients to undergo routine biochemical and hematological testing including CBC, KFT, LFT, PT/INR, electrolytes baseline and daily along with ABG (Arterial Blood gas) analysis.
  4. Patients with ascites to be tested for presence or absence of SBP (Spontaneous Bacterial Peritonitis).
  5. Cultures to be sent as based on clinical parameter of the patient.
  6. All correctable causes for intra abdominal hypertension to be corrected including electrolyte imbalance, grade III ascites, intra abdominal infection.
  7. Symptoms- Absent bowel sounds (BS)= no BS detected by auscultation. Vomiting/regurgitation= any visible regurgitation of gastric contents; Diarrhoea= liquid stool > or =3 times/day; Bowel distension= suspected clinically and radiologically confirmed; Large gastric residual volume (GRV) of >or =500 ml/24 h on a single day or > 200ml at any time of the day.
  8. Per abdomen findings to be checked daily including presence of bowel sounds, tenderness, development of abdominal distension, abdominal girth monitoring and abdominal pressure monitoring.
  9. Patients who develop feed intolerance will be included.
  10. Feed intolerance to be defined as per study definition (3 out of 5 symptoms).
  11. Measurement of GRV (Gastric residual volume) to be done at 4 hourly interval.
  12. Methods for measuring GRV by either gravity drainage by connecting a gastric tube to a drainage bag for 10min or by manual aspiration of content using a 50ml syringe.
  13. Once feed intolerance develop than every 6 hourly intra abdominal pressure monitoring and abdominal girth monitoring to be done (24)
  14. Intra bladder pressure to be measured using Foleys manometer technique (25).
  15. Pressure measured in cm of water to be converted into mm of Hg.
  16. X ray abdomen supine to look for bowel distension, defined as more than 3 cm for small bowel and more than 5 cm in large bowel.
  17. Development of intra abdominal hypertension based on intra abdominal pressure.
  18. Patient to be stratified according to the grade of intra-abdominal hypertension.
  19. After correction of all correctable causes, if feed intolerance persists, then patient to be randomized by block randomization method into 3 arms, metaclopromide group, erythromycin group or placebo group.
  20. Daily assessment of bowel sounds, abdominal pressure, abdominal girth every 6 hourly and gastric residual volume to be noted every 4 hourly.
  21. Response of therapy to be assessed at 24 hours in each arm.
  22. Response to be assessed by resolution of feed intolerance or initiation of entral nutrition.
  23. Metoclopromide to be given 10mg iv 8 hourly.
  24. Erythromycin to be given 70mg iv 12 hourly (26).
  25. Placebo arm to receive normal saline in 10ml syring twice daily.
  26. After 24 hours of treatment if symptoms do not resolve than rescue treatment will be given to each arm which may include continuation of prokinetics, add on prokinetic, flatus tube insertion for bowel decompression, upgradation of antibiotics or search for any other cause, as per the patient response.
  27. Therapy to continue for a total duration of 72 hours.
  28. If there is no response at 72 hours, than study stops.
  29. If patient responds to given treatment, study to continue for a total duration of 7 days.
  30. Assessment to continue in each arm for a maximum period of 7 days.

Condition or disease Intervention/treatment Phase
Cirrhosis Drug: Metaclopramide Drug: Erythromycin Other: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 83 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis- A Randomized Placebo Controlled Study
Actual Study Start Date : September 24, 2015
Actual Primary Completion Date : August 31, 2017
Actual Study Completion Date : August 31, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis

Arm Intervention/treatment
Experimental: Metaclopromide group Drug: Metaclopramide
23. Metoclopromide to be given 10mg iv 8 hourly

Experimental: Erythromycin group Drug: Erythromycin
Erythromycin to be given 70mg iv 12 hourly.

Placebo Comparator: Placebo group Other: Placebo



Primary Outcome Measures :
  1. Resolution of feed intolerance at 24 hours with improvement in 3 or more points and initiation of entral feeding. [ Time Frame: 24 hours ]
    Feed intolerance to be defined as 3/5 symptoms which include gastric residual volume > 500 ml /day,absence of bowel sounds,vomitting/regurgitation,diarrhoea and bowel distension


Secondary Outcome Measures :
  1. Survival [ Time Frame: 72 hours ]
  2. Survival [ Time Frame: 7 days ]
  3. Number of patients with Initiation of entral nutrition more than 50%. of recommended nutrition (Kcal/kg body weight/day). [ Time Frame: 72 hours ]
    Feed intolerance is also defined when entral nutrition provided < 20Kcal/kg body weight/day.

  4. Number of patients with resolution of atleast 2 out of 5 symptoms in all the 3 groups. [ Time Frame: 72 hours ]
    Feed intolerance to be defined as 3/5 symptoms which include gastric residual volume > 500 ml /day,absence of bowel sounds,vomitting/regurgitation,diarrhoea and bowel distension

  5. Number of patients with resolution of sepsis, shock, organ failure in all the 3 groups. [ Time Frame: 7 days ]
  6. Number of patients without Ventilatory support in all the 3 groups. [ Time Frame: 7 days ]
  7. Number of patients without inotropic supports in all the 3 groups. [ Time Frame: 7 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

1. Patients who develop new onset feed intolerance to enteral nutrition

Exclusion Criteria:

  1. Any patient with current or past surgical abdomen including mechanical obstruction, mesenteric ischemia, perforation or requiring abdominal surgery.
  2. Patients receiving enteral nutrition through gastrostomy or jejunostomy.
  3. Patients in whom, prokinetics are contraindicated or are allergic to the same.
  4. Patients who received prokinetic more than one day prior to the start of enteral feeding.
  5. Patients with uncontrolled sepsis with DIC.
  6. Requirement of two or more vasopressors.
  7. Organ failure requiring high inotropic support.
  8. Advanced cardiopulmonary disease, with prior history of arrhythmias, structural heart disease.
  9. History of traumatic brain injury, raised intracranial pressure, history of myasthenia gravis.
  10. Endocronolgic illnesses: Hypothyroidism, hypoparathyroidism
  11. Connective tissue diseases (systemic sclerosis, dermatomyositis or polymyositis, systemic lupus erythematosis, amyloidosis).
  12. Known case of diabetes with diabetic gastroparesis
  13. Pregnancy
  14. Patients or concerned family member who fail to give consent for study enrollment
  15. Age less than 18 years and more than 70 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02528760


Locations
Layout table for location information
India
Institute of liver and Biliary Sciences
New Delhi, Delhi, India, 110070
Sponsors and Collaborators
Institute of Liver and Biliary Sciences, India

Layout table for additonal information
Responsible Party: Institute of Liver and Biliary Sciences, India
ClinicalTrials.gov Identifier: NCT02528760     History of Changes
Other Study ID Numbers: ILBS-Cirrhosis-005
First Posted: August 19, 2015    Key Record Dates
Last Update Posted: November 21, 2017
Last Verified: September 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Erythromycin
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Liver Cirrhosis
Fibrosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Metoclopramide
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Dopamine D2 Receptor Antagonists
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors